BRNS VS FONR Stock Comparison
Performance
BRNS10/100
10/100
BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
FONR10/100
10/100
FONR returned 2.31% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Earnings
BRNS100/100
100/100
BRNS has missed earnings 1 times in the last 20 quarters.
FONR
"Earnings" not found for FONR
Volatility
BRNS50/100
50/100
BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
FONR59/100
59/100
FONR has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.
Sentiment
BRNS
"Sentiment" not found for BRNS
FONR75/100
75/100
FONR had a bullish sentiment score of 75.20% across Twitter and StockTwits over the last 12 months. It had an average of 3.17 posts, 0.00 comments, and 0.00 likes per day.
Technicals
BRNS
"Technicals" not found for BRNS
FONR86/100
86/100
FONR receives a 85 of 100 based on 14 indicators. 12 are bullish, 2 are bearish.
Profit
BRNS
"Profit" not found for BRNS
FONR73/100
73/100
Out of the last 20 quarters, FONR has had 20 profitable quarters and has increased their profits year over year on 7 of them.
All score calculations are broken down here to help you make more informed investing decisions
Barinthus Biotherapeutics plc American Depositary Shares Summary
Nasdaq / BRNS
Healthcare
Biotechnology
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Fonar Corporation Summary
Nasdaq / FONR
Healthcare
Medical - Devices
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare BRNS to other companies in the same or a similar industry.